Stressed gastrointestinal bleeding prevention new options.

SHANGHAI, China, July 30, 2020 -- AstraZeneca announced today that the State Drug Administration (NMPA) has officially approved a letter-resistant ® needle (injected with sodium Aiomeprazole) to prevent stress ulcer bleeding in severely ill patients.
as an inhibitor of primary proton pump, the new adaptation of injectable aiomeprazole sodium has been approved for the prevention of stressed gastrointestinal bleeding in China.
the human body in the severe trauma, complex surgery, critical diseases and other severe stress state of acute digestive tract mucosa erosion, ulcers, bleeding and other lesions collectively known as stress mucosa lesions (SRMD), serious cases can lead to perforation of the digestive tract to further worsen the overall condition of the patient.
in China, stress mucosal disease is a common complication in critically ill patients, and studies have shown that the mortality rate of stress ulcer bleeding in critically ill patients is as high as 50%, so it is important to prevent the occurrence of this complication.
the approval of this adaptation is based on the results of a random, double-blind, parallel grouping, multi-center independent phase III clinical study conducted in China that evaluated the efficacy and safety of the intravenous dose of sodium aiomeprazole 40mg twice a day and continuous intravenous injection of simetinin in china to prevent gastrointestinal bleeding in severe patients in China.
the results of this randomized clinical trial of simetinas positive for control, the results of the treatment assessment, Esiomeprazole group than the western metametin group of digestive tract bleeding rate is lower (Esometine group 2.7%, simetin4 4.6%), Aiomemetin 40 mg can effectively prevent severe patients on gastrointestinal bleeding twice.
the safety characteristics of the Aiomeprazole group were similar to those of the simitin group, and in the case of severe diseases in China, the overall tolerance was good and no new safety problems were found.
the main researcher of the study, the Chinese Medical Association, vice chairman of the external science branch of the gastroenterology group Professor Qin Xinyu said, "As the original research proton pump inhibitors, the resistance has the characteristics of fast and long-lasting acid suppression, has accompanied Chinese doctors for more than a decade, its efficacy and safety has been fully confirmed."
listed drugs through scientific research to accumulate evidence-based evidence and broaden the evidence, can help clinical compliance with the specification of prevention and treatment, drug use is evidence-based, conducive to promoting rational use of drugs.
"AstraZeneca has listed the world's first proton pump inhibitor omeprazole and its second-generation product, Ameprazola, and in the field of digestive diseases, our scientific exploration of patients' treatment needs has never stopped," said Mr. Rae Minglong, General Manager of AstraZeneca China.
is pleased to see that Esomeprazole sodium needle has become the Chinese market after omeprazole injections with the digestive tract ulcer bleeding prevention and treatment of the certificate of products, Hope that in the future for more Chinese patients to provide a full range of digestive protection.
" Source: MedSci Original !-- Content Presentation Ends -- !-- Determine signed-up end.